Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.
暂无分享,去创建一个
R. Tuttle | F. Vaisman | R. Corbo | D. Momesso | M. Vaisman | S. P. Yang | D. Bulzico
[1] S. Mandel,et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[2] I. Ganly,et al. Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. , 2015, Human pathology.
[3] R. Tuttle,et al. Update on differentiated thyroid cancer staging. , 2014, Endocrinology and metabolism clinics of North America.
[4] F. Vaisman,et al. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer , 2014, Journal of Endocrinological Investigation.
[5] R. Tuttle,et al. Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm , 2013, Journal of thyroid research.
[6] R. Tuttle,et al. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. , 2013, Thyroid : official journal of the American Thyroid Association.
[7] R. Tuttle,et al. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: a practical approach to clinical decision making. , 2013, Oral oncology.
[8] S. Larson,et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. , 2013, Thyroid : official journal of the American Thyroid Association.
[9] T. Uruno,et al. Thyroid Lobectomy for Papillary Thyroid Cancer: Long-term Follow-up Study of 1,088 Cases , 2013, World Journal of Surgery.
[10] S. Mandel,et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. , 2012, Thyroid : official journal of the American Thyroid Association.
[11] R. Tuttle,et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy , 2012, Clinical endocrinology.
[12] T. Montesano,et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? , 2012, The Journal of clinical endocrinology and metabolism.
[13] J. Shah,et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. , 2012, Surgery.
[14] D. Papathanassiou,et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. , 2012, The Journal of clinical endocrinology and metabolism.
[15] R. Tuttle,et al. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. , 2011, Thyroid : official journal of the American Thyroid Association.
[16] G. Cevenini,et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. , 2011, European journal of endocrinology.
[17] R. Tuttle,et al. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer , 2011, Clinical endocrinology.
[18] J. Shah,et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.
[19] L. Ceriani,et al. Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma , 2009, Head & neck.
[20] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[21] L. Ward,et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. , 2009, Arquivos brasileiros de endocrinologia e metabologia.
[22] T. Sebo,et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. , 2008, Surgery.
[23] Tuttle Rm. Risk-Adapted Management of Thyroid Cancer , 2008 .
[24] I. Hay. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma , 2006, Journal of surgical oncology.
[25] W. Wiersinga,et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.
[26] L. Duntas,et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. , 2004, European journal of endocrinology.
[27] A. Shaha. Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer , 2004, The Laryngoscope.
[28] B. O'Sullivan,et al. A comparison of different staging systems predictability of patient outcome , 1997, Cancer.